环球印务(002799) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥633,569,317.10, a decrease of 40.44% compared to the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥14,339,265.38, representing a decline of 162.94% year-on-year[4]. - The basic earnings per share for the period was -¥0.04, down 162.94% from the previous year[4]. - Total operating revenue for Q3 2023 was CNY 1,961,875,424.13, a decrease of 18.4% compared to CNY 2,401,523,534.17 in the same period last year[27]. - The net profit for the third quarter was 37,326,739.30 CNY, a decrease of 61.0% compared to 95,883,296.21 CNY in the same period last year[30]. - Operating profit decreased to 48,525,020.13 CNY, down 53.7% from 104,724,011.82 CNY year-over-year[30]. - Basic and diluted earnings per share were both 0.14 CNY, down from 0.26 CNY in the previous year[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,405,438,371.02, a decrease of 7.64% from the end of the previous year[4]. - Total assets as of September 30, 2023, were CNY 2,405,438,371.02, down from CNY 2,604,514,578.00 at the beginning of the year, indicating a decrease of 7.6%[25]. - Total liabilities decreased to CNY 693,281,589.54 from CNY 919,683,735.82, a decline of 24.6%[25]. - The company’s total liabilities decreased significantly, with a 100% reduction in non-current liabilities due within one year, reflecting loan repayments[8]. Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥85,246,267.39, an increase of 56.63%[4]. - The cash flow from operating activities showed a net increase of 85,246,267.39 CNY, up from 54,425,322.06 CNY in the previous year[32]. - The total cash flow from investment activities was negative at -211,468,187.39 CNY, worsening from -50,296,585.80 CNY year-over-year[34]. - The company reported a significant increase in interest income to 7,344,462.54 CNY, compared to 1,639,864.26 CNY in the previous year[30]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,975[12]. - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 36.42% of shares, totaling 116,550,000 shares[12]. Impairment and Provisions - The company has recognized an impairment provision of RMB 56,891,633.89 for accounts receivable, which will reduce the net profit attributable to shareholders by RMB 41,530,892.74, accounting for 46.06% of the last audited annual net profit[15][16]. - The cumulative impairment provision for accounts receivable from the client "Brainstorm" is RMB 69,169,338.37, with a cumulative provision ratio of 25%[14]. - The company incurred a credit impairment loss of -61,531,277.48 CNY, compared to -6,476,596.98 CNY in the previous year, indicating a significant increase in credit risk[30]. Projects and Subsidiaries - The company reported a significant increase in construction in progress, rising by 172.24% to ¥254,813,254.53 due to ongoing projects[8]. - The company is constructing the "Global Printing Expansion and Green Packaging Intelligent Manufacturing Industrial Park" project, which includes a primary and secondary pharmaceutical packaging production center and a technology R&D center[17]. - The company has established a new subsidiary, Beijing Jinyinlian, with a registered capital of no less than RMB 80 million for a new materials project, with a total investment of no less than RMB 100 million[18]. - The project for the new materials company is currently under construction as planned[18]. Operational Efficiency - The company completed the liquidation plan for its associate company Shaanxi Yongxin, which is expected to have a minimal impact on its business segments[19]. - The company is focusing on reducing related party transactions through the liquidation of Shaanxi Yongxin, which is expected to streamline operations[19]. Costs and Expenses - Total operating costs for Q3 2023 were CNY 1,860,569,322.87, down 19.3% from CNY 2,304,995,777.38 year-on-year[27]. - Research and development expenses were 38,908,050.91 CNY, down 7.4% from 42,078,542.54 CNY year-over-year[30]. - The company’s financial expenses decreased by 42.39% to ¥8,007,819.93, mainly due to increased interest income[8].